



GEORGIA DEPARTMENT
OF COMMUNITY HEALTH

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health
2 Peachtree Street – **5th Floor Board Room**
Atlanta, Georgia 30303

March 17, 2016



This page intentionally left blank



DRUG UTILIZATION REVIEW BOARD MEETING

AGENDA

2 Peachtree Street - 5th Floor DCH Board Room

Atlanta, Georgia 30303

Thursday, March 17, 2016

9:00 a.m. to 1:00 p.m.

CALL TO ORDER	<i>Gurinder Doad, MD, Chair</i>
COMMENTS FROM THE DEPARTMENT	<i>Peter D’Alba, RPh, Pharmacy Director, DCH</i>
MINUTES FROM PREVIOUS MEETING	<i>Chair</i>
EXTERNAL COMMENTS SESSION	<i>Chair</i>
CLINICAL REVIEWS	<i>Afzal Mistry, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
<ul style="list-style-type: none"> ➤ New Drugs <ul style="list-style-type: none"> ● Corlanor, Entresto ● Daklinza, Technivie, Zepatier ● Praluent, Repatha ➤ Therapeutic Classes <ul style="list-style-type: none"> ● Atypical Antipsychotics, including new drug Rexulti ● Antihemophilic Recombinant Factor VIIIs, including new products Adynovate and Nuwiq ● Antihemophilic Recombinant Factor IXs ➤ Supplemental Rebate Classes 	
ADJOURNMENT OF OPEN SESSION	<i>Chair</i>
EXECUTIVE SESSION	<i>Steve Liles, PharmD, Senior Director, Goold</i>
RECONVENING OF OPEN SESSION	<i>Chair</i>
BOARD’S RECOMMENDATIONS AND VOTES	<i>Chair</i>
FUTURE AGENDA ITEMS	<i>Chair</i>
ADJOURNMENT OF MEETING	<i>Chair</i>



This page intentionally left blank

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Tuesday, December 15, 2015**

MEMBERS PRESENT

Osgood (Drew) A. Miller, R.Ph., Chair
Gurinder J.S. Doad, M.D., Vice-Chair
Mia Avery, Pharm.D.
Douglas Collins, M.D.
Rod M. Duraski, M.D., FACP, MBA
Deborah W. Fincher, M.S., R.Ph.
M. Celeste Fowler, Pharm.D.
Yolanda P. Graham, M.D.
Mary S. Harris, Ph.D.
Burton L. Lesnick, M.D., FAAP
J. Russell May, Pharm.D.
Brent L. Rollins, R.Ph., Ph.D.
Robert E. Shervette III, M.D.
Danny A. Toth, R.Ph.

MEMBERS ABSENT

Robyn Lorys, Pharm.D.

Staff

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services
Turkesia Robertson-Jones, Pharm.D., Pharmacy Operations Manager, Pharmacy Services
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services
Lori Garner, MHS, MBA, R.Ph., Pharmacist, Pharmacy Services
Patricia Z. Jeter, MPA, R.Ph., Pharmacist, Pharmacy Services
Rose Marie Duncan, MBA, Program Associate, Pharmacy Services
Eunice Wang, Pharm.D. Candidate

NorthStar HealthCare Consulting

Emily Baker, Pharm.D., BCPS, MHA, MBA, President
Tara R. Cockerham, Pharm.D., Clinical Programs Director
Afzal "Fez" Mistry, Pharm.D., Clinical Pharmacist

Catamaran

Susan McCreight, Sr. Director, Public Sector Account Management
Mark Hall, MBA, PMP, Account Manager
Talmahjia "Tami" Sweat, Pharm.D., Clinical Systems Product Manager

Goold Health Services

Steve Liles, Pharm.D., Sr. Director, Pharmacy Services
Doug Martin, Pharm.D., Pharmacy Project Manager

Amerigroup

Kelli W. Ferrell, R.Ph., MS

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its fourth meeting for the calendar year on December 15, 2015. The Chair, Osgood (Drew) A. Miller, R.Ph., called the meeting to order at 9:36am.

Comments from the Department

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services, commented on the following items:

1. New Members Welcomed – Douglas Collins, M.D., Burton L. Lesnick, M.D., FAAP, Rod M. Duraski, M.D., FACP, MBA, Mary S. Harris, Ph.D., and Danny A. Toth, R.Ph.
2. 2016 DURB Chair and Vice-Chair – Gurinder J.S. Doad, M.D., Chair and Deborah W. Fincher, M.S., R.Ph., Vice-Chair.
3. Thank You – Drew Miller, R.Ph., Chair, was thanked for his hard work during his tenure.
4. Continuity of Care – Quarterly meetings planned with the CMO's to discuss transitional care.

Minutes from the Previous Meeting

Chair Miller asked for corrections or changes to the minutes from the September 24, 2015 meeting. There were no corrections. A motion was made (Robert E. Shervette III, M.D.), seconded (J. Russell May, Pharm.D) and carried to approve the minutes as written.

External Comments Session

External comments were presented to the Board from the following:

- Tara Cockerham, Pharm.D., provided an overview of written comments received by the following:
 - J. Martin Johnston, M.D., FAAP, Director, Hematology/Oncology, The Children's Hospital – preferred status for Factor VIII and IX products, specifically Eloctate and Alprolix
 - Chrissy Kennedy, RN, BSN, Director of Nursing, InTouch Pharmacy – equal and open access for all patients for newer agents
 - Edward M. Burke (hemophilia patient) – access to all medicines
 - Thomas B. MacCallum, Cottrill's Specialty Pharmacy – uniform patient access to all hemophilia products
- Liliana Gomez (son has hemophilia) – quality of life with less infusions, having choice to choose medication, allow open access

Disclosure forms were completed by J. Martin Johnston, M.D., Chrissy Kennedy, RN, BSN, Edward M. Burke, Thomas B. MacCallum and Liliana Gomez and were reviewed by the Department.

Adjournment of Open Session

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES**

Tuesday, December 15, 2015

Health, Goold Health Services, NorthStar HealthCare Consulting, and OptumRx. Pharmacy students, Hazel Lacson (Mercer), Raiza Gandola (Mercer), Nathan Williams (Mercer), Pamiz Alibhal (Mercer), Bahareh Kashani (PCOM), and Andrew May (UGA), attended the closed session with Board members. A motion was made by Robert E. Shervette III, M.D. and seconded by Rod M. Duraski, M.D., to adjourn the open session and approve the closed session. There was a unanimous vote approving the closed session. The Chairman, Drew Miller, R.Ph., adjourned the open session at approximately 10:00 am, at which time members took a break then reconvened for the executive (closed) session.

Executive Session

The Executive Session was held from 10:06am to 11:21am.

Reconvening of Open Session

The DUR Board reconvened for the open session at 11:30am.

Manufacturers' Forum

Tara Cockerham, Pharm.D., reviewed information regarding the Manufacturers' Forum that was provided in the Manufacturer Information section in the DUR Board binder. A total of seven (7) manufacturers participated or provided information regarding the following drugs discussed at the December 2015 DURB meeting:

Manufacturers	Drugs
AstraZeneca	Movantik
Shire	Natpara
Biogen	Alprolix, Elocate
Novartis	Farydak, Promacta, Signifor LAR
Astellas	Cresemba
Emergent	Ixinity
Allergan	Avycaz

There were no questions or comments.

The next forum will be held on Tuesday, February 9, 2016 and Thursday, February 11, 2016 from 9am-5pm at the NorthStar Healthcare Consulting office: 1121 Alderman Drive, Suite 112, Alpharetta, GA 30005.

New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Antiinfectives, Beta-Lactams – Cephalosporins and Beta-Lactamase Inhibitors	<i>Avycaz, Zerbaxa</i>	Tara Cockerham, Pharm.D.

Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Tuesday, December 15, 2015

Gastrointestinal, Bile Acid Agents	<i>Cholbam</i>	Tara Cockerham, Pharm.D..
Antiinfectives, Antifungals – Invasive Aspergillosis and Mucormycosis	<i>Cresemba</i>	Tara Cockerham, Pharm.D.
Antineoplastics, Multiple Myeloma	<i>Farydak</i>	Tara Cockerham, Pharm.D.
Antihemophilic Products, Factor IX Recombinant	<i>Ixinity</i>	Tara Cockerham, Pharm.D.
Antihemophilic Products, Factor VIII Recombinant	<i>Novoeight</i>	Afzal Mistry, Pharm.D.
Gastrointestinal, Opioid-Induced Constipation Agents	<i>Movantik</i>	Afzal Mistry, Pharm.D.
Hormone Modifiers, Parathyroid Agents	<i>Natpara</i>	Afzal Mistry, Pharm.D.
Thrombopoietin Receptor Agonists	<i>Nplate</i>	Afzal Mistry, Pharm.D.
Hormone Modifiers, Acromegaly Agents	<i>Signifor LAR</i>	Afzal Mistry, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Avycaz/Zerbexa – use of Probenecid
- Cholbam – only available from one provider
- Ixinity – support the Department to meet with manufactures for all drugs in this class to discuss and encourage the provision of supplemental rebates for this class of drugs and look at this class again in March.

The Board voted and made recommendations for all new drug reviews noted in the Board’s Recommendations to the Department.

Non-Supplemental Rebate Drugs – New Clinical Information Review

Clinical updates to the Non-Supplemental Rebate categories were listed in the Non-Supplemental Rebate section of the DURB binder and presented to the Board by Dr. Afzal “Fez” Mistry. The following therapeutic categories had updates:

Drug Class/Name
Antiinfectives, Antimalarials
Antiinfectives, Antimycobacterials

There were no questions or comments.

The Board voted and made recommendations for all non-supplemental rebate drugs noted in the Board's Recommendations to the Department.

Follow-Up Items

Retrospective DUR Intervention Outcomes were provided in the Follow-Up Items section of the DUR Board binder.

DCH Decisions

DCH Decisions from the September 2015 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Utilization Trends Review

Utilization trends for Georgia Medicaid Fee-for-Service were provided in detail in the Utilization Trends Review section of the DUR Board binder. It was suggested to look at utilization in children <18 years old utilizing neuroleptics, antipsychotics, ADHD, etc.

Drug Information

Information from the following was provided in detail in the Drug Information section of the DUR Board binder used for this meeting:

- Drug Update Newsletter
- Horizon Watch Report
- Patent Expiration Report
- Clinical Compass Newsletter

Future Agenda Items

There were no future agenda items noted.

Upcoming Meetings

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board
2 Peachtree Street NW
5th Floor Board Room
Atlanta, Georgia 30303

Thursday, March 17, 2016
Thursday, June 16, 2016
Tuesday, September 13, 2016
Tuesday, December 13, 2016
- Manufacturers' Forum
NorthStar Healthcare Consulting
1121 Alderman Drive
Suite 112

Thursday, February 11, 2016
Tuesday, February 9, 2016 (if needed)
Thursday, May 12, 2016
Thursday, August 11, 2016
Thursday, November 10, 2016

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL). All motions and votes are noted in Attachment A.

New Drugs and Non-Supplemental Rebate Classes

Antiinfectives, Beta-Lactams, Cephalosporins and Beta-Lactamase Inhibitors

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Avycaz (Intravenous) Vial* and *Zerbaxa (Intravenous) Vial*.

Gastrointestinal, Bile Acid Agents

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Cholbam (Oral) Capsule* and *Non-Preferred* status with *Prior Authorization* for *Chenodal (Oral) Tablet*.

Antiinfectives, Antifungals, Invasive Aspergillosis and Mucormycosis

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Cresemba (Oral) Capsule*, *Ambisome (Intravenous) Vial*, and *Candidas (Intravenous) Vial*.

Antineoplastics, Multiple Myeloma

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Farydak (Oral) Capsule*.

Antihemophilic Products, Factor IX Recombinant

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Ixinity (Intravenous) Vial*.

Antihemophilic Products, Factor VIII Recombinant

The DUR Board recommended *Preferred* status for *Novoeight (Intravenous) Vial*.

Gastrointestinal, Opioid-Induced Constipation Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Movantik (Oral) Tablet* and *Relistor (Subcutaneous) Injection*.

Hormone Modifiers, Parathyroid Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Natpara (Subcutaneous) Cartridge*.

Thrombopoietin Receptor Agonists

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Nplate (Subcutaneous) Vial*.

Hormone Modifiers, Acromegaly Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Signifor LAR (Intramuscular) Vial* and *Somavert (Subcutaneous) Vial*.

Antiinfectives, Toxoplasmosis

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Daraprim (Oral) Tablet*.

Hematopoietics, Iron Injectables

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Sodium Ferric Gluconate Complex (Intravenous) Vial*.

Conclusion

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting. Chair Miller adjourned the meeting at 1:04pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____
DAY OF _____, 2016.

Osgood (Drew) A. Miller, R.Ph., Chair



Children's Hospital

at Memorial University Medical Center

25 November 2015

DCH Pharmacy Unit
2 Peachtree Street
Atlanta, GA 30303

Re: **Alprolix and Eloctate**

To whom it may concern:

I am a pediatric hematologist and Hemophilia Treatment Center director, writing in reference to Factor VIII and Factor IX products and, specifically, the prolonged-half-life products, Alprolix and Eloctate. I would like to see these products (and all factor products) available as preferred agents for my patients with hemophilia.

I think that there may be confusion regarding these products and their dosing. Eloctate and Alprolix are genetically modified versions of, respectively, factor VIII and factor IX that are designed to exhibit a prolonged half-life. For this reason, patients receiving routine prophylactic factor infusions can typically be **dosed less frequently** than with "conventional" factor products. For example, one of my severe hemophilia A patients is currently administering Advate via Portacath on a M/W/F schedule; his total weekly dose is 9200 units. He and I are discussing a switch to Eloctate; my initial dosing recommendation would be two doses per week, one of 2500 units and one of 5000 units, for a weekly total of 7500 units. I plan to monitor his factor VIII "trough" levels and consider adjusting his regimen to dose once every 4 or 5 days, in which case his total weekly dose may ultimately be even less. Based on published data, this treatment should be as effective as his current regimen.

My understanding is that the cost of Eloctate, on a unit-for-unit basis is 25-30% higher than "conventional" factor VIII products. **This apparent extra cost is essentially negated if fewer units are administered.** Meanwhile, the patient benefits considerably from the convenience of less-frequent dosing. This also decreases the cost of supplies necessary for administration and, statistically speaking, **reduces the risk** of infectious complications from intravenous (or central venous catheter) administration.

Other prolonged-half-life factor VIII and factor IX products are coming onto the market in the next few years. There is every reason to assume that **many/most hemophilia patients will eventually be treated with one of these products.** In general, I expect all of these products to be at least as effective as the current "conventional" products, with advantages as noted above.

It is my great hope that I will be able to offer these products to my patients with a minimum of effort/inconvenience for them and for myself. You are in a position to make that happen.

Thank you for your time.

J. Martin Johnston, MD, FAAP
Director, Hematology/Oncology
The Children's Hospital @ Memorial University Medical Center
Associate Professor of Pediatrics
Mercer University School of Medicine
Savannah, GA

DURB Meeting
RE: Alprolix and Eloctate
December 8, 2015
2 Peachtree St. Atlanta, GA 30303

To Whom It May Concern:

I am the Director of Nursing for InTouch Pharmacy and I want to share my experiences with the long acting medications, Eloctate and Alprolix. Having been a HTC nurse for three years, I saw the struggles the patients on prophylaxis went through of having to infuse three times a week up to every other day. I became the director of nursing for InTouch Pharmacy in 2014 and since then witnessed great things with the switch to the long acting agents. One particular family told me after they switched to Eloctate, it made their lives with hemophilia more manageable, even with just one less infusion a week. The mother explained it was always a fight between her and her teenager and now with one less infusion a week, their relationship has improved and the patient's compliance has been almost perfect.

I am lucky to be a nurse during this time of hemophilia products because there are so many options. The drug companies are working hard to help these patients and families manage their disease by offering long acting medications. We are lucky to have new innovative therapies that will decrease the number of infusions, likely increasing compliance which will in turn decrease hospital admissions and costs. I heard another family claim that cutting back on the number of infusions with their long acting drug helped them decide that a port was not needed. Since they decided against the port, there is no need to go to the ER for every fever, no risk of port infections or malfunctions and hospital stays.

This new product from Biogen plus any new long acting drug that comes to market helps our patients become more compliant and have fewer bleeds, less joint damage, and a better quality of life. Even though the new products may cost more per unit, they are given less frequently and the dosing may be kept the same, depending on the patient and are as effective as the previous treatment therapy.

Alprolix and Eloctate and Adynovate that just came to market this week will set the stage as the preferred agents for patients with hemophilia. Please consider open and equal access to all therapies for all patients.

Thank you,



Chrissy Kennedy, RN, BSN
InTouch Pharmacy

Edward M. Burke

485 Westlake Blvd. Apt. 66
Palm Harbor, FL. 34683



December 8, 2015

Georgia Department of Community Health
2 Peachtree St.
Atlanta, GA. 30303

To Members of the Drug Utilization Review Board

I am a fifty seven year old male with factor VIII severe Hemophilia A. And I am grateful for the opportunity to share with you my personal experience with treating my hemophilia with assistance from a Medicaid program. I am one of twenty thousand people with hemophilia that contracted HCV, and HIV from FDA approved blood products, thirty years ago. And while I am grateful to be a thirty plus year survivor, as well as having the honor to work with my District Rep. Newt Gingrich during those very difficult times, to support a Bill that would greatly improve the collection, monitoring and testing of all donated blood and blood products.

I want to share with you today that each person with FactorVIII hemophilia may have a better outcome from a hematologic episode due to the fact that one factor reacts better then another. Therefore, it is imperative to provide access to all medications and therapeutic categories to affect an efficient recovery from such episodes.

Another reason to provide all medications and therapeutic categories is that I have witnessed in the past that some homecare companies that contracted with that State's Medicaid program would deny a more expensive factor product to a patient, solely for a larger positive revenue, and not the patients most effective factor VIII product, that could significantly improve the desired outcome. An outcome that was agreed upon by the patient and his or her hematologist.

I thank you again for the opportunity to share my personal experiences with you. And hope it provides a clearer vision of these individuals and their needs.

Sincerely,

Edward M. Burke





HELPING YOU MAINTAIN A HEALTHY, ACTIVE LIFESTYLE.

December 8th, 2015

Georgia Department of Community Health
2 Peachtree Street
Atlanta, GA 30303

To The Members of the Drug Utilization Review Board:

Cottrill's Specialty Pharmacy is dedicated to our customers and patients. We have served as a traditional and independent local pharmacy for over 100 years. In addition to providing retail pharmacy prescriptions and supplies, Cottrill's Specialty Pharmacy offers expertise in servicing patients with bleeding disorders as well as other therapy areas. Our team has extensive experience in the bleeding disorder arena including decades of years of collective experience in advocacy, industry, personal experience and community involvement. We are dedicated to supporting patients with bleeding disorders so they may lead healthy, productive lives.

As we are looking forward to working with Georgia Medicaid in the future to provide care for your patients, we would like to take this opportunity to express our support for uniform patient access to all hemophilia products. With many new treatment options available, and several others arriving in the new future, we believe it is in the patients best clinical interest to have all options available. As you are aware, hemophilia patients clotting systems respond differently to each and every clotting product available, therefore it is imperative to have equal access to all products to allow the patient and the medical team to provide the best care and ensure the best clinical outcomes.

We would like to thank you for the opportunity to share our experiences and thoughts. We hope this provides insight to the patients and their needs.

Sincerely,

A handwritten signature in black ink, appearing to read "Thomas J. Nuttle", is written over a light blue horizontal line.

Thomas J. Nuttle FACHE
VP Business Development



ACCREDITED
SPECIALTY PHARMACY

1-844-COTTRILLS • fax: (716) 508-8482

www.cottrillsparmacy.com

4919 ELLICOTT ROAD • ORCHARD PARK, NEW YORK 14127

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

	New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
	Antihemophilic Products, Factor VIII Recombinant	Novoeight (Intravenous) Vial	P	P		
	Board Members - Present <small>(Strike out, when absent)</small>	Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		√	√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)	√		√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	14	0	0
	Board Members - Absent					
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antihemophilic Products, Factor IX Recombinant	Ixivity (Intravenous) Vial	NPPA	NPPA	Board strongly support meeting with all manufactueres to provide Supplemental Rebates. Take a relook at this class at the Board meeting in March.	
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.			√		
4 Doad, Gurinder J.S., M.D.- Vice			√		
5 Fincher, Deborah W., M.S., R.Ph.			√		
6 Fowler, M. Celeste, Pharm.D.			√		
7 Graham, Yolanda, M.D.			√		
8 Harris, Mary, Ph.D.			√		
9 Lesnick, Burton, M.D.			√		
10 May, J. Russell (Rusty)	√		√		
11 Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12 Rollins, Brent L., R.Ph., Ph.D.			√		
13 Shervette III, Robert E., M.D.			√		
14 Toth, Danny, R.Ph.		√	√		
TOTAL			14	0	0
Board Members - Absent					
1 Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antiinfectives, Antifungals, Invasive Aspergillosis and Mucormycosis		Ambisome (Intravenous) Vial	P	NPPA		
		Cancidas (Intravenous) Vial	P	NPPA		
		Cresemba (Oral) Capsule	NPPA	NPPA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		√	√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)	√		√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

	New Drug				
	Drug	PDL Status	Motion - Recommendations	Additional Comments	
	Antiinfectives, Beta-Lactams - Cephalosporins & Beta-Lactamase Inhibitors	Avycaz (Intravenous) Vial	NPPA	NPPA	
		Zerbaxa (Intravenous) Vial	NPPA	NPPA	
	Board Members - Present <small>(Strike out, when absent)</small>	Motion Maker (v)	Seconded By (v)	VOTES	
				YES (v)	NO (v) ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√	
2	Collins, Douglas, M.D.			√	
3	Duraski, Rod, M.D.			√	
4	Doad, Gurinder J.S., M.D.- Vice	√		√	
5	Fincher, Deborah W., M.S., R.Ph.			√	
6	Fowler, M. Celeste, Pharm.D.			√	
7	Graham, Yolanda, M.D.			√	
8	Harris, Mary, Ph.D.			√	
9	Lesnick, Burton, M.D.			√	
10	May, J. Russell (Rusty)		√	√	
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√	
12	Rollins, Brent L., R.Ph., Ph.D.			√	
13	Shervette III, Robert E., M.D.			√	
14	Toth, Danny, R.Ph.			√	
			TOTAL	14	0 0
	Board Members - Absent				
1	Lorys, Robyn Pharm.D.				

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments		
Antineoplastics, Multiple Myeloma	Farydak (Oral) Capsule	PPA	PPA			
Board Members - Present <small>(Strike out, when absent)</small>	Motion Maker (v)	Seconded By (v)	VOTES			
			YES (v)	NO (v)	ABSTAIN (v)	
1 Avery, Mia, Pharm.D.			√			
2 Collins, Douglas, M.D.			√			
3 Duraski, Rod, M.D.			√			
4 Doad, Gurinder J.S., M.D.- Vice			√			
5 Fincher, Deborah W., M.S., R.Ph.	√		√			
6 Fowler, M. Celeste, Pharm.D.			√			
7 Graham, Yolanda, M.D.			√			
8 Harris, Mary, Ph.D.			√			
9 Lesnick, Burton, M.D.			√			
10 May, J. Russell (Rusty)			√			
11 Miller, Osgood (Drew) A. R.Ph. - Chair			√			
12 Rollins, Brent L., R.Ph., Ph.D.			√			
13 Shervette III, Robert E., M.D.			√			
14 Toth, Danny, R.Ph.		√	√			
		TOTAL	14	0	0	
Board Members - Absent						
1 Lorys, Robyn Pharm.D.						

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Gastrointestinal, Bile Acid Agents	Cholbam (Oral) Capsule	PPA	PPA		
Board Members - Present <i>(Strike out, when absent)</i>	Motion Maker (v)	Seconded By (v)	VOTES		
			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.			√		
4 Doad, Gurinder J.S., M.D.- Vice			√		
5 Fincher, Deborah W., M.S., R.Ph.	√		√		
6 Fowler, M. Celeste, Pharm.D.			√		
7 Graham, Yolanda, M.D.			√		
8 Harris, Mary, Ph.D.			√		
9 Lesnick, Burton, M.D.			√		
10 May, J. Russell (Rusty)			√		
11 Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12 Rollins, Brent L., R.Ph., Ph.D.		√	√		
13 Shervette III, Robert E., M.D.			√		
14 Toth, Danny, R.Ph.			√		
TOTAL			14	0	0
Board Members - Absent					
1 Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Gastrointestinal, Opioid-Induced Constipation Agents	Movantik (Oral) Tablet	NPPA	NPPA		
	Relistor (Subcutaneous) Injection	P	NPPA		
Board Members - Present <small>(Strike out, when absent)</small>	Motion Maker (v)	Seconded By (v)	VOTES		
			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.			√		
4 Doad, Gurinder J.S., M.D.- Vice			√		
5 Fincher, Deborah W., M.S., R.Ph.			√		
6 Fowler, M. Celeste, Pharm.D.		√	√		
7 Graham, Yolanda, M.D.	√		√		
8 Harris, Mary, Ph.D.			√		
9 Lesnick, Burton, M.D.			√		
10 May, J. Russell (Rusty)			√		
11 Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12 Rollins, Brent L., R.Ph., Ph.D.			√		
13 Shervette III, Robert E., M.D.			√		
14 Toth, Danny, R.Ph.			√		
TOTAL			14	0	0
Board Members - Absent					
1 Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Hormone Modifiers, Acromegaly Agents		Signifor LAR (Intramuscular) Vial	NPPA	NPPA		
		Somavert (Subcutaneous) Vial	P	NPPA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.		√	√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.	√		√		
10	May, J. Russell (Rusty)			√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Hormone Modifiers, Parathyroid Agents		Natpara	NP	NPPA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)		√	√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.	√		√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

December 15, 2015

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Thrombopoietin Receptor Agonists	Nplate (Subcutaneous) Vial	PPA	NPPA		
Board Members - Present <small>(Strike out, when absent)</small>	Motion Maker (v)	Seconded By (v)	VOTES		
			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Duraski, Rod, M.D.			√		
4 Doad, Gurinder J.S., M.D.- Vice			√		
5 Fincher, Deborah W., M.S., R.Ph.			√		
6 Fowler, M. Celeste, Pharm.D.			√		
7 Graham, Yolanda, M.D.		√	√		
8 Harris, Mary, Ph.D.			√		
9 Lesnick, Burton, M.D.			√		
10 May, J. Russell (Rusty)			√		
11 Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12 Rollins, Brent L., R.Ph., Ph.D.			√		
13 Shervette III, Robert E., M.D.			√		
14 Toth, Danny, R.Ph.	√		√		
TOTAL			14	0	0
Board Members - Absent					
1 Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antiinfectives, Beta Lactams-Beta-Lactamase Inhibitors and Penicillins				NO CHANGES		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.	√		√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)			√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.		√	√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antiinfectives, Antimalarials				NO CHANGES		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.	✓		✓		
2	Collins, Douglas, M.D.			✓		
3	Duraski, Rod, M.D.			✓		
4	Doad, Gurinder J.S., M.D.- Vice			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D.			✓		
7	Graham, Yolanda, M.D.			✓		
8	Harris, Mary, Ph.D.		✓	✓		
9	Lesnick, Burton, M.D.			✓		
10	May, J. Russell (Rusty)			✓		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			✓		
12	Rollins, Brent L., R.Ph., Ph.D.			✓		
13	Shervette III, Robert E., M.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antiinfectives, Antimycobacterials				NO CHANGES		
Board Members - Present		Motion	Seconded	VOTES		
<i>(Strike out, when absent)</i>		Maker (v)	By (v)	YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)	√		√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.		√	√		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antiinfectives, Toxoplasmosis		Daraprim (Oral) Tablet	P	PPA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.	√		√		
7	Graham, Yolanda, M.D.		√	√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)			√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
				TOTAL	14	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Gastrointestinal, Bile Acid Agents		Chenodal (Oral) Tablet	P	NPPA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.	√		√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)		√	√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Hematopoietics, Iron Injectables		Sodium Ferric Gluconate Complex (Intravenous) Vial	P	NPPA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice	√		√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)			√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.		√	√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
				TOTAL	14	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments		
Luteinizing-Hormone Releasing Hormone/Gonadotropin-Releasing Hormone Agonist Analogs				NO CHANGES			
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES			
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)	
1	Avery, Mia, Pharm.D.			√			
2	Collins, Douglas, M.D.			√			
3	Duraski, Rod, M.D.		√	√			
4	Doad, Gurinder J.S., M.D.- Vice			√			
5	Fincher, Deborah W., M.S., R.Ph.			√			
6	Fowler, M. Celeste, Pharm.D.			√			
7	Graham, Yolanda, M.D.			√			
8	Harris, Mary, Ph.D.			√			
9	Lesnick, Burton, M.D.			√			
10	May, J. Russell (Rusty)			√			
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√			
12	Rollins, Brent L., R.Ph., Ph.D.	√		√			
13	Shervette III, Robert E., M.D.			√			
14	Toth, Danny, R.Ph.			√			
			TOTAL	14	0	0	
Board Members - Absent							
1	Lorys, Robyn Pharm.D.						

Drug Utilization Review Board

Motions - Votes - Non-SR Class Review

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Short Bowel Syndrome				NO CHANGES		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.	✓		✓		
2	Collins, Douglas, M.D.			✓		
3	Duraski, Rod, M.D.			✓		
4	Doad, Gurinder J.S., M.D.- Vice			✓		
5	Fincher, Deborah W., M.S., R.Ph.			✓		
6	Fowler, M. Celeste, Pharm.D.			✓		
7	Graham, Yolanda, M.D.			✓		
8	Harris, Mary, Ph.D.			✓		
9	Lesnick, Burton, M.D.		✓	✓		
10	May, J. Russell (Rusty)			✓		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			✓		
12	Rollins, Brent L., R.Ph., Ph.D.			✓		
13	Shervette III, Robert E., M.D.			✓		
14	Toth, Danny, R.Ph.			✓		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board

Motions - Votes - **Non-SR Class Review**

December 15, 2015

NON-SR CLASS		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Vitamin D Analogs				NO CHANGES		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		√	√		
2	Collins, Douglas, M.D.			√		
3	Duraski, Rod, M.D.			√		
4	Doad, Gurinder J.S., M.D.- Vice			√		
5	Fincher, Deborah W., M.S., R.Ph.			√		
6	Fowler, M. Celeste, Pharm.D.			√		
7	Graham, Yolanda, M.D.			√		
8	Harris, Mary, Ph.D.			√		
9	Lesnick, Burton, M.D.			√		
10	May, J. Russell (Rusty)	√		√		
11	Miller, Osgood (Drew) A. R.Ph. - Chair			√		
12	Rollins, Brent L., R.Ph., Ph.D.			√		
13	Shervette III, Robert E., M.D.			√		
14	Toth, Danny, R.Ph.			√		
			TOTAL	14	0	0
Board Members - Absent						
1	Lorys, Robyn Pharm.D.					

Drug Utilization Review Board Meeting

December 15, 2015

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
Drug Reviews			
Antiinfectives, Beta-Lactams, Cephalosporins and Beta-Lactamase Inhibitors			
	Avycaz (Intravenous) Vial	NP/PA	NP/PA
	Zerbaxa (Intravenous) Vial	NP/PA	NP/PA
Gastrointestinal, Bile Acid Agents			
	Cholbam (Oral) Capsule	P/PA	P/PA
	Chenodal (Oral) Tablet	P	NP/PA
Antiinfectives, Antifungals, Invasive Aspergillosis and Mucormycosis			
	Cresemba (Oral) Capsule	NP/PA	NP/PA
	Ambisome (Intravenous) Vial	P	NP/PA
	Cancidas (Intravenous) Vial	P	NP/PA
Antineoplastic, Multiple Myeloma			
	Farydak (Oral) Capsule	P/PA	P/PA
Antihemophilic Products, Factor IX Recombinant			
	Ixinity (Intravenous) Vial	NP/PA	NP/PA
Antihemophilic Products, Factor VIII Recombinant			
	Novoeight (Intravenous) Vial	P	P
Gastrointestinal, Opioid-Induced Constipation Agents			
	Movantik (Oral) Tablet	NP/PA	NP/PA
	Relistor (Subcutaneous) Injection	P	NP/PA
Hormone Modifiers, Parathyroid Agents			
	Natpara (Subcutaneous) Cartridge	NP	NP/PA
Thrombopoietin Receptor Agonists			
	Nplate (Subcutaneous) Vial	P/PA	NP/PA

Hormone Modifiers, Acromegaly Agents			
	Signifor LAR (Intramuscular) Vial	NP/PA	NP/PA
	Somavert (Subcutaneous) Vial	P	NP/PA
Antiinfectives, Toxoplasmosis			
	Daraprim (Oral) Tablet	P	P/PA
Hematopoietics, Iron Injectables			
	Sodium Ferric Gluconate Complex (Intravenous) Vial	P	NP/PA

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization



Manufacturers' Forum
ANNOUNCEMENT
NorthStar HealthCare Consulting
Georgia Department of Community Health

On behalf of the Georgia Department of Community Health (DCH) and in service to the Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review Board (DURB), NorthStar HealthCare Consulting (NHC), in conjunction with OptumRx, announces the Manufacturers' Forum occurring on Thursday, May 12, 2016.

Date: Thursday, May 12, 2016 from 9am-5pm EST

Location: NorthStar HealthCare Consulting
1121 Alderman Drive, Suite 112
Alpharetta, GA 30005

Appointments: *The Manufacturers' Forum is by appointment only.* Appointments may be requested and will be scheduled **after** the Drugs Under Review are posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Forum. Manufacturers with drugs up for review at the current DURB meeting will be granted preference when seeking appointments. All requests for appointments must be made in writing to GAMedicaid@nhc-llc.com and include the drug name. New drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.

Guidelines for Participation:

- To ensure equitable treatment of all manufacturers, individual manufacturer participation shall be limited to one 30-minute time segment per Forum. The presentation shall be limited to approximately 20 minutes with 10 minutes for questions and answers.
- Manufacturer presentations may be audio-recorded for review after the Forum and the associated information shall be presented by NHC in summary fashion at regularly scheduled DURB meetings.
- For new drugs, manufacturers are highly encouraged to present all clinical information pertinent and relevant to current NHC clinical presentations to the DURB, to DCH drug benefit plan design and to other drugs within the class.
- For existing drugs, manufacturers are highly encouraged to present new clinical information since the drug was last reviewed by the DURB, especially clinical information related to comparisons of other drugs within the class.
- An electronic **one-page** summary (front only, font 10, not including references) of each drug presentation, **factually based**, in a stand-alone, user-friendly document should be provided one week prior to the presentation via email to GAMedicaid@nhc-llc.com and please include a pronunciation guide of the drug's brand and generic names. The one-page summary along with relevant questions and answers related to the presentation will be provided to the DURB as well as published in the DURB meeting handout that is provided to the public at the meetings and on the DCH website at <http://dch.georgia.gov/durb-meeting-information>.

Comments and Inquiries:

- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **Preferred Drug List, Prior Authorization Criteria, Manufacturers' Forum or DURB** should submit these in writing to GAMedicaid@nhc-llc.com.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **supplemental rebates** should submit these in writing to GAOffers@ghsinc.com.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **claims processing** or **drug benefit plan design** should submit these to the address or phone number below:

OptumRx, Georgia Department of Community Health
Windward Fairways I, 3025 Windward Plaza Suite 200, Alpharetta, Georgia 30005
Phone: 770-776-2000 Fax: 770-776-2050



This page intentionally left blank



**Georgia Department of Community Health (GDCH)
Opportunities for Pharmaceutical Manufacturer Input on Clinical
Recommendations and Clinical Management Strategies by the
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

Ongoing Opportunity:

DUR Board Meeting Process: Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via GAMedicaid@nhc-llc.com and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov**

Presentation Opportunity:

Manufacturers' Forum: A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.



**Questions not addressed in this document may be sent to NorthStar
HealthCare Consulting by e-mail: GAMedicaid@nhc-llc.com**

2016

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Peachtree Street, N.W.

5th Floor Board Room

Atlanta, Georgia 30303

Thursday, June 16, 2016: 9:30am – 2:30pm

Tuesday, September 13, 2016: 9:30am – 1:30pm

Tuesday, December 13, 2016: 9:30am – 1:30pm

Manufacturers' Forum

NorthStar HealthCare Consulting

1121 Alderman Drive

Suite 112

Alpharetta, Georgia 30005

Thursday, May 12, 2016: 9:00am – 5:00pm

Thursday, August 11, 2016: 9:00am – 5:00pm

Thursday, November 10, 2016: 9:00am – 5:00pm

This page intentionally left blank

Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise
Gurinder J.S. Doad, Chair	M.D., Ph.D.	Family Practice
Deborah W. Fincher, Vice-Chair	R.Ph., M.S.	HIV/AIDS Pharmacy
Mia Avery	Pharm.D.	Oncology Pharmacy
Douglas C. Collins	M.D.	Hematology/Oncology
Rod M. Duraski	M.D., FACP, MBA	Internal Medicine
M. Celeste Fowler	Pharm.D., HCMBA	Hospital Pharmacy
Yolanda P. Graham	M.D.	Child and Adolescent Psychiatry
Mary S. Harris	Ph.D.	Health Care Information/Education Research
Burton L. Lesnick	M.D., FAAP	Pediatrics/Pediatric Pulmonology
Robyn Lorys	Pharm.D.	Managed Care
J. Russell May	Pharm.D.	Academia - Professor
Drew A. Miller	R.Ph.	Retail Pharmacy
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor
Robert E. Shervette, III	M.D.	Child and Adolescent Psychiatry
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans